KERRY REYNOLDS: Open Payments
NPI 1306034616 · OGDEN, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$793 in 48 payments from 16 companies in 2025. Trend: 2023 $872 · 2024 $712 · 2025 $793
Food & beverage: $793
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $144 |
| GlaxoSmithKline, LLC. | 5 | $90 |
| PFIZER INC. | 4 | $84 |
| ViiV Healthcare Company | 4 | $78 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $76 |
| Astellas Pharma US Inc | 2 | $62 |
| Lilly USA, LLC | 3 | $48 |
| Baxter Healthcare | 1 | $32 |
| AstraZeneca Pharmaceuticals LP | 2 | $32 |
| Gilead Sciences, Inc. | 2 | $31 |
Products named: VRAYLAR, APRETUDE, CAPLYTA, Veozah, NURTEC ODT, QULIPTA, TRELEGY ELLIPTA, MOUNJARO.
Industry payments across UT — which companies pay providers there.
